Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

China’s SIPO Voids Patent for Gilead’s Viread

publication date: Jul 30, 2013
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
China's State Intellectual Property Office (SIPO) has invalidated the patent for Viread, a treatment for hepatitis B and HIV/AIDS developed by Gilead Sciences. SIPO agreed with Aurisco, a China API maker, that Viread was not a novel drug because its active ingredient was discovered in the Czech Republic in 1985. Gilead had already lost patent protection for the drug in India and Brazil. Earlier this year, Gilead made an undisclosed settlement with Teva Pharma to end its challenge to Viread's US patent. More details....

Stock Symbols: (NSDQ: GILD) (NYSE: TEVA)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...